185 related articles for article (PubMed ID: 17851230)
1. Role of aldose reductase in the peritoneal changes of patients undergoing peritoneal dialysis.
Hasuike Y; Moriguchi R; Hata R; Miyagawa K; Kuragano T; Aizawa M; Yamamoto S; Yanase K; Izumi M; Tanimoto T; Nakanishi T
Am J Nephrol; 2007; 27(6):622-9. PubMed ID: 17851230
[TBL] [Abstract][Full Text] [Related]
2. Influence of pH-neutral peritoneal dialysis solution.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():68-71. PubMed ID: 12402590
[TBL] [Abstract][Full Text] [Related]
3. The alteration of dialysate cancer antigen 125 concentration under a biocompatible bicarbonate peritoneal dialysis solution and the preservation of the mesothelial cell viability.
Theodoridis M; Passadakis P; Kriki P; Gioka T; Panagoutsos S; Mourvati E; Thodis E; Kantartzi K; Vargemezis V
Ren Fail; 2008; 30(2):161-7. PubMed ID: 18300115
[TBL] [Abstract][Full Text] [Related]
4. Preservation of peritoneal catheter for prevention of encapsulating peritoneal sclerosis.
Moriishi M; Kawanishi H; Kawai T; Takahashi S; Hirai T; Shishida M; Watanabe H; Takahashi N
Adv Perit Dial; 2002; 18():149-53. PubMed ID: 12402608
[TBL] [Abstract][Full Text] [Related]
5. Clinical biocompatibility of a neutral peritoneal dialysis solution with minimal glucose-degradation products--a 1-year randomized control trial.
Szeto CC; Chow KM; Lam CW; Leung CB; Kwan BC; Chung KY; Law MC; Li PK
Nephrol Dial Transplant; 2007 Feb; 22(2):552-9. PubMed ID: 17005526
[TBL] [Abstract][Full Text] [Related]
6. Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis.
Ho-dac-Pannekeet MM; Hiralall JK; Struijk DG; Krediet RT
Adv Perit Dial; 1997; 13():17-22. PubMed ID: 9360644
[TBL] [Abstract][Full Text] [Related]
7. Immunopathological changes in a uraemic rat model for peritoneal dialysis.
Zareie M; De Vriese AS; Hekking LH; ter Wee PM; Schalkwijk CG; Driesprong BA; Schadee-Eestermans IL; Beelen RH; Lameire N; van den Born J
Nephrol Dial Transplant; 2005 Jul; 20(7):1350-61. PubMed ID: 15840671
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal conversion of mesothelial cells as a mechanism responsible for high solute transport rate in peritoneal dialysis: role of vascular endothelial growth factor.
Aroeira LS; Aguilera A; Selgas R; Ramírez-Huesca M; Pérez-Lozano ML; Cirugeda A; Bajo MA; del Peso G; Sánchez-Tomero JA; Jiménez-Heffernan JA; López-Cabrera M
Am J Kidney Dis; 2005 Nov; 46(5):938-48. PubMed ID: 16253736
[TBL] [Abstract][Full Text] [Related]
9. The triggering of human peritoneal mesothelial cell apoptosis and oncosis by glucose and glycoxydation products.
Boulanger E; Wautier MP; Gane P; Mariette C; Devuyst O; Wautier JL
Nephrol Dial Transplant; 2004 Sep; 19(9):2208-16. PubMed ID: 15213320
[TBL] [Abstract][Full Text] [Related]
10. Peritoneal dialysis fluid-induced changes of the peritoneal membrane are reversible after peritoneal rest in rats.
Zareie M; Keuning ED; ter Wee PM; Beelen RH; van den Born J
Nephrol Dial Transplant; 2005 Jan; 20(1):189-93. PubMed ID: 15572385
[TBL] [Abstract][Full Text] [Related]
11. Cancer antigen 125: a bulk marker for the mesothelial mass in stable peritoneal dialysis patients.
Visser CE; Brouwer-Steenbergen JJ; Betjes MG; Koomen GC; Beelen RH; Krediet RT
Nephrol Dial Transplant; 1995; 10(1):64-9. PubMed ID: 7724031
[TBL] [Abstract][Full Text] [Related]
12. Effects of glucose-free dialysis solutions on human peritoneal mesothelial cells.
Chang JM; Lin SP; Lai YH; Chen HC
Am J Nephrol; 2007; 27(2):206-11. PubMed ID: 17377374
[TBL] [Abstract][Full Text] [Related]
13. Evaluation of effluent markers cancer antigen 125, vascular endothelial growth factor, and interleukin-6: relationship with peritoneal transport.
Rodrigues A; Martins M; Santos MJ; Fonseca I; Oliveira JC; Cabrita A; Melo e Castro J; Krediet RT
Adv Perit Dial; 2004; 20():8-12. PubMed ID: 15384786
[TBL] [Abstract][Full Text] [Related]
14. Do interleukin-6, hyaluronan, soluble intercellular adhesion molecule-1 and cancer antigen 125 in dialysate predict changes in peritoneal function? A 1-year follow-up study.
Martikainen T; Ekstrand A; Honkanen E; Teppo AM; Grönhagen-Riska C
Scand J Urol Nephrol; 2005; 39(5):410-6. PubMed ID: 16257844
[TBL] [Abstract][Full Text] [Related]
15. [Morpho-functional study of peritoneum in peritoneal dialysis].
Bertoli SV; Buzzi L; Ciurlino D; Maccario M; Martino S
G Ital Nefrol; 2003; 20(2):160-5. PubMed ID: 12746801
[TBL] [Abstract][Full Text] [Related]
16. Variability of effluent cancer antigen 125 and interleukin-6 determination in peritoneal dialysis patients.
Lopes Barreto D; Coester AM; Noordzij M; Smit W; Struijk DG; Rogers S; de Waart DR; Krediet RT
Nephrol Dial Transplant; 2011 Nov; 26(11):3739-44. PubMed ID: 21498425
[TBL] [Abstract][Full Text] [Related]
17. Morpho-functional study of peritoneum in peritoneal dialysis patients.
Bertoli SV; Buzzi L; Ciurlino D; Maccario M; Martino S
J Nephrol; 2003; 16(3):373-8. PubMed ID: 12832736
[TBL] [Abstract][Full Text] [Related]
18. Transport of peritoneal membrane assessed before and after the start of peritoneal dialysis.
La Milia V; Limardo M; Cavalli A; Crepaldi M; Locatelli F
Nephrol Dial Transplant; 2009 Sep; 24(9):2894-8. PubMed ID: 19349295
[TBL] [Abstract][Full Text] [Related]
19. Necessity of correcting cancer antigen 125 appearance rates by body surface area.
Kawanishi H; Moriishi M; Harada Y; Sakikubo E; Nagai T; Tsuchiya S
Adv Perit Dial; 2000; 16():22-5. PubMed ID: 11045255
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of peritoneal transport and membrane status in peritoneal dialysis: focus on incident fast transporters.
Rodrigues AS; Martins M; Korevaar JC; Silva S; Oliveira JC; Cabrita A; Castro e Melo J; Krediet RT
Am J Nephrol; 2007; 27(1):84-91. PubMed ID: 17284895
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
